Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 62-year-old male with a history of alcohol abuse was admitted with a headache and rapidly progressing altered consciousness that led to coma over several hours. Blood and cerebrospinal fluid cultures were positive for Edwardsiella tarda. Despite prompt treatment initiation, the patient died on the third hospital day. Autopsy showed meningitis of the entire cerebrum with ventriculitis, and alcoholic fatty liver was observed. Clinicians should be cognizant of E. tarda meningoencephalitis, a rare presentation which can be associated with poor outcomes in patients with excessive alcohol consumption and alcoholic liver disease.
 ...
PMID:An Autopsy Case of Edwardsiella tarda Meningoencephalitis. 3028 23

Autosomal recessive polycystic kidney disease (ARPKD) is the most common childhood-onset ciliopathy. Intracranial aneurysms (ICA) are a serious complication of autosomal dominant polycystic kidney disease (ADPKD). However, there are only three reports about ICA in an adult patient with ARPKD. We describe a rare case of a 29-year-old man with ARPKD presenting with subarachnoid hemorrhage secondary to a ruptured intracranial aneurysm. The diagnosis of ARPKD was at the age of eight years based on typical ultrasonography findings with polycystic kidneys and liver disease. Magnetic resonance cholangiography showed a nonobstructive dilatation of intrahepatic bile ducts. Liver biopsy showed hepatic fibrosis. None of the family members was affected. At the age of 15 years, he had progressed to end-stage kidney disease, and hemodialysis was started. The patient had always a severe arterial hypertension. At the age of 29 years, he complained of headaches with an uncontrolled hypertension and disturbance of consciousness, computed tomography angiography showed subarachnoid hemorrhage and multiple cerebral aneurysms. Early neurologic screening of intracranial aneurysm should be recommended in ARPKD like in ADPKD patients.
 ...
PMID:Ruptured intracranial aneurysm and recessive polycystic kidney Disease: A Rare Association. 3146 60

Pretomanid was approved by the USFDA, via the Limited Population Pathway for Antibacterial and Antifungal Drugs, as part of a three-drug regimen with bedaquiline and linezolid for treatment of extensively drug-resistant and treatment intolerant and non-responsive multi-drug resistant tuberculosis. The recommended dose of pretomanid is 200 mg once daily with food. The objective of this work was to retrospectively evaluate that recommended dose by means of exposure-response (E-R) modeling applied to outcomes of both efficacy and safety. Cox proportional hazard modeling was used, with steady-state average pretomanid concentration as the exposure metric. The efficacy outcome was time to sputum culture conversion to negative (TSCC). The safety outcomes were times to first occurrence of adverse events in classes selected either from pretomanid's Investigator Brochure or from the NDA submission as recognized safety signals for pretomanid based on preclinical as well as clinical experience. Significant E-R relationships were found for TSCC and for two adverse event classes, Vomiting (a single preferred term) and GI Symptoms (a collection of related terms). No significant E-R relationships were found for the single preferred terms Nausea, ALT Increased, AST Increased, and Headache, and for the collections Hepatic Disorders, Transaminases Increased, Skin and Subcutaneous Tissue Disorders, and Headache. The results suggest that the recommended dose of pretomanid, 200 mg given in the fed state, is appropriate over the range of pharmacokinetic exposure.
 ...
PMID:The Clinical Dose of Pretomanid: An Exposure-Response Perspective. 3307 60


<< Previous 1 2 3 4 5